DEP Combine With PD-1 Antibody as an Initial Treatment for EBV-HLH
Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
This study aimed to investigate the efficacy and safety of DEP (liposomal doxorubicin,
etoposide and methylprednisolone) together with PD-1 antibody as an initial treatment for EBV
associated hemophagocytic lymphohistiocytosis.